Shares of Windtree Therapeutics, Inc. (NASDAQ:WINT – Get Rating) are going to split on Friday, November 25th. The 2-1 split was announced on Friday, November 25th. The newly issued shares will be distributed to shareholders after the closing bell on Friday, November 25th.
Windtree Therapeutics Stock Down 4.6 %
Windtree Therapeutics stock opened at $0.17 on Wednesday. The firm has a market cap of $5.06 million, a price-to-earnings ratio of -0.11 and a beta of 0.24. The stock has a fifty day simple moving average of $0.25 and a two-hundred day simple moving average of $0.38. Windtree Therapeutics has a 12 month low of $0.15 and a 12 month high of $1.78. The company has a current ratio of 2.54, a quick ratio of 2.54 and a debt-to-equity ratio of 0.86.
Analyst Upgrades and Downgrades
Separately, Oppenheimer reduced their target price on Windtree Therapeutics to $2.00 in a report on Thursday, November 17th.
Institutional Trading of Windtree Therapeutics
Windtree Therapeutics Company Profile
Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension.
- Get a free copy of the StockNews.com research report on Windtree Therapeutics (WINT)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
Receive News & Ratings for Windtree Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.